Replies to post #134434 on Biotech Values

[mcbio]

I do not follow the PCSK9 connection. To cancel a program with seemingly great potential, IMO, requires more than a cursory statement or blame the FDA. Thus, my sense for some bitterness and/or regret. I am not discounting the cancer issue, but this is part of any approval process.

I take it at face value. I don't think they would cancel the program just by being behind REGN as it is a large enough market for multiple entrants and their drug targeted PCSK9 in a different way than REGN's drug I believe; I think it's the safety questions and the assumption that very large and expensive trials will be required. The article that was linked to by the other poster seemed to give credence to the potential safety issues of targeting PCSK9.